INTRODUCTION

Significant changes in the patient population and disease landscape, and no new antifungal approved in over a decade, have contributed to growing unmet needs in antifungal treatment.

Rezafungin acetate, a novel echinocandin designed to address limitations in the current antifungal armamentarium, has a distinctive PK profile that enables high, front-loaded drug exposure and once-weekly dosing, which correlates with potential benefits to efficacy and safety. Rezafungin is being developed for the prevention and treatment of invasive fungal infections. STRIVE (NCT02734862) is a global Phase 2 trial evaluating the safety and efficacy of IV rezafungin in treatment of candidemia and/or invasive candidiasis compared with standard of care (IV caspofungin + optional oral stepdown [fluconazole]).

An analysis by geographic region of the completed Part A of STRIVE was conducted to inform interpretation of results and Phase 3 development.

METHODS

Patients were randomized to 1 of 3 treatment arms according to the study design (Figure 1) as previously described.4

Figure 1. STRIVE trial design.

Data were stratified by enrollment region and analyzed for differences in demographics, baseline characteristics, treatment patterns, and outcomes.

RESULTS

Data for 62 patients enrolled in Europe (EU) and 45 patients enrolled in North America (NA) were available for analysis (Table 1).

Table 1. Patient demographics and characteristics at baseline

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Rezafungin 400/400 mg</th>
<th>Rezafungin 200/200 mg</th>
<th>Caspofungin 70/50 mg</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, n/N (%)</td>
<td>7/13 (53.8)</td>
<td>11/18 (61.1)</td>
<td>3/14 (21.4)</td>
<td>21/45 (46.7)</td>
</tr>
<tr>
<td>EU</td>
<td>14/22 (63.6)</td>
<td>11/18 (61.1)</td>
<td>14/22 (63.6)</td>
<td>39/62 (62.9)</td>
</tr>
<tr>
<td>Age, y mean ± SD [≥18 y]</td>
<td>46.8 ± 12 y</td>
<td>52.1 ± 14 y</td>
<td>52.4 ± 16 y</td>
<td>50.7 ± 14 y</td>
</tr>
<tr>
<td>EU</td>
<td>63.0 ± 15 y</td>
<td>61.9 ± 13 y</td>
<td>66.0 ± 16 y</td>
<td>63.7 ± 15 y</td>
</tr>
<tr>
<td>NA</td>
<td>74.6 ± 17.8</td>
<td>85.3 ± 26.5</td>
<td>73.8 ± 13.5</td>
<td>78.7 ± 21.2</td>
</tr>
<tr>
<td>Weight, kg mean ± SD</td>
<td>72.5 ± 15.5</td>
<td>65.8 ± 19.8</td>
<td>75.3 ± 15.9</td>
<td>71.4 ± 17.2</td>
</tr>
</tbody>
</table>

Patients in the EU were older than in NA; however, illness severity (APACHE II scores) was similarly distributed between regions. EU patients were predominantly male (62.9%) and white (96.8%). The NA population was balanced between male and female; 26.7% were Black or African-American. In addition to weighing more, NA patients had higher BMI (not shown).

RESULTS (cont’d)

Efficacy (mITT population)

No meaningful trends in efficacy were noted (Table 2); however, subgroup sizes limit interpretation.

Table 2. Rates of overall response by region (mITT).

<table>
<thead>
<tr>
<th>Overall Response-Success (Day 14)</th>
<th>Caspofungin</th>
<th>Rezafungin</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>400 mg Wk1</td>
<td>400 mg WkQ</td>
</tr>
<tr>
<td>EU</td>
<td>57.1% (12/21)</td>
<td>76.5% (13/17)</td>
</tr>
<tr>
<td>NA</td>
<td>58.3% (7/12)</td>
<td>64.3% (9/14)</td>
</tr>
</tbody>
</table>

Treatment Patterns (Safety Population)

While most patients overall received 8–14 days of IV treatment; 23% of EU patients received >14 days versus 9% in NA.

Distribution of Candida spp. at Enrollment (mITT Population)

Non-albicans Candida comprised 60.3% of baseline isolates in the EU with similar proportions of C. glabrata, C. parapsilosis, and C. tropicalis. In NA, C. albicans was predominant (56.4%), followed by C. glabrata (17.9%) (Figure 1).

Figure 1. Candida spp. isolated at Baseline

CONCLUSIONS

- No differentiating trends in illness severity or outcomes by geographic region were seen in STRIVE (Part A)
- In general, EU patients were older and NA patients were heavier
- Non-albicans Candida spp. were more prevalent in the EU
- Longer durations of IV treatment were more often administered in the EU
- Subgroups identified by demographics and baseline characteristics may warrant future additional analyses

REFERENCES

4. Thompson GR, et al. Rezafungin Clinical Safety and Efficacy in Patients with Candidemia and/or Invasive Candidiasis in the Randomized, Double-blind, Multicenter, Phase 2 STRIVE Trial. IDWeek 2018.

ACKNOWLEDGMENTS

Editorial support was provided by T. Chung (Sorbint Medical) and funded by Cidara Therapeutics.